1379825-89-4

Basic information

• Product Name: (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile
• CAS NO: 1379825-89-4
• Molecular Weight: 0
• Mol File: 1379825-89-4.mol
• Article Data: 23

Chemical Properties

• CAS DataBase Reference: (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile(1379825-89-4)
• EPA Substance Registry System: (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile(1379825-89-4)

Safety Data

• Hazardous Substances Data: 1379825-89-4(Hazardous Substances Data)

Usage

Description

(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile is a complex organic compound characterized by a benzene ring with a nitrile group, a fluoro group, and a keto group attached to a furan ring. This highly reactive and potentially toxic chemical is utilized in organic synthesis and pharmaceutical research due to its unique structure, which allows for participation in various chemical reactions. It serves as a valuable building block for the development of new drugs and materials. However, its potentially harmful properties necessitate careful handling and storage.

Uses

Used in Organic Synthesis:
(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile is used as a key intermediate in organic synthesis for the creation of various complex molecules. Its unique structure and reactivity enable the formation of a wide range of compounds, making it a versatile building block in this field.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile is used as a starting material for the development of new drugs. Its complex structure and ability to participate in multiple chemical reactions make it a promising candidate for the synthesis of novel therapeutic agents.
Used in Material Science:
(Z)-2-fluoro-5-((3-oxoisobenzofuran-1(3H)-ylidene)methyl)benzonitrile is also utilized in material science for the development of new materials with specific properties. Its unique structure and reactivity contribute to the creation of materials with tailored characteristics for various applications.

Upstream product

• 119-67-5 o-carboxybenzaldehyde 
• 61260-15-9 dimethyl (3-oxo-1,3-dihydroisobenzofuran-1-yl)phosphonate 
• 179897-89-3 5-Bromo-2-fluoro-benzonitrile 
• 4741-67-7 3-oxo-1,3-dihydroisobenzofuran-1-ylphosphonic acid 
• 218301-22-5 2-fluoro-5-formylbenzonitrile 
• 16859-59-9 3-hydroxy-1(3H)-isobenzofuranone 
• 77771-02-9 3-bromo-4-fluorobenzaldehyde 
• 17858-15-0 trimethylsilyl 2-{(diethoxyphosphoryl)[(diethoxyphosphoryl)oxy]methyl}benzoate 

Downstream Products

• 763111-49-5 4-[[4-fluoro-3-[(hexahydro-1H-1,4-diazepin-1-yl)carbonyl]phenyl]methyl]-1(2H)-phthalazinone 

Relevant articles and documents

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)

Poly(ADP-ribose) polymerase-1 (PARP-1), a critical DNA repair enzyme in the base excision repair pathway, has been pursued as an attractive cancer therapeutic target. Intervention with PARP-1 has been proved to be more sensitive to cancer cells carrying BRCA1/2 mutations. Several PARP-1 inhibitors have been available on market for the treatment of breast, ovarian and prostatic cancer. Promisingly, the newly developed proteolysis targeting chimaeras (PROTACs) may provide a more potential strategy based on the degradation of PARP-1. Here we report the design, synthesis, and evaluation of a proteolysis targeting chimaera (PROTAC) based on the combination of PARP-1 inhibitor olaparib and the CRBN (cereblon) ligand lenalidomide. In SW620 cells, our probe-quality degrader compound 2 effectively induced PARP-1 degradation which results in anti-proliferation, cells apoptosis, cell cycle arresting, and cancer cells migratory inhibition. Thus, our findings qualify a new chemical probe for PARP-1 knockdown.

Design, synthesis and activity evaluation of new phthalazinone parp inhibitors

Poly(ADP-ribose)polymerase (PARP) is a significant therapeutic target for the treatment of numerous human diseases. Olaparib has been approved as a PARP inhibitor. In this paper, a series of new compounds were designed and synthesized with Olaparib as the lead compound. In order to evaluate the inhibitory activities against PARP1 of the synthesized compounds, in vitro PARP1 inhibition assay and intracellular PARylation assay were conducted. The results showed that the inhibitory activities of the derivatives were related to the type of substituent and the length of alkyl chain connecting the aromatic ring. 3-(4,5-Dimethyl- 2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)-based assay also proved that these compounds demonstrating strong inhibition to PARP1 also have high anti-proliferative activities against BRCA2-deficient cell line (Capan-1). Analysis of the entire results suggest that compound 23 with desirable inhibitory efficiency may hold promise for further in vivo exploration of PARP inhibition.

ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS

The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.